Sun Pharma looks reasonable post recent correction: Sudip Bandopadhyay

In an interaction with ET Now, Sudip Bandopadhyay, market expert, shares his views on the midsized pharma sector.

ET Now: Do you have a particular thought process on a midsized pharma name because off and on while we talk about the Sun Pharma’s and the Cipla’s the real gains have been made by people who bought into Anuh Pharma or a Strides Arcolab or a Sequent Scientific those are the ones that actually made a big dash over the last 12 months?

Sudip Bandyopadhyay: I agree with you in fact I do not remember whether you recollect but I have been always positive on midcap Pharma. I have been actually not buying or recommending buy into Sun Pharma’s of the world. I have been bullish on Glenmark, I continue to remain bullish there. I have been consistently bullish on Ipca Laboratories and Indoco, both even today I like.

There is again that Dishman, there is Strides lot of things corporate action was happening in Strides so one has to understand the specific corporate action which happening in Stride to take a position but otherwise the companies I mentioned all have been doing very well and it is definitely worth investing in these midsized pharma companies even today.

Having said that, post correction Sun Pharma at current level looks good, Ranbaxy integration has been a challenge for the company but things will fall in place and things are falling in place. Sun Pharma at current level is good.